Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra- abdominal infections

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 10, 1997, Pages 2312-2316

  Citron, Diane M ^a   Appleman, Maria D ^a  

^a LAC USC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLONE DERIVATIVE; TROVAFLOXACIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; DRUG ACTIVITY; ENTEROBACTERIACEAE; PRIORITY JOURNAL; PSEUDOMONAS; STREPTOCOCCACEAE;

EID: 0030863172     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.10.2312     Document Type: Article

References (12)

1. Citron, D. M., N. Fiorentino, M. Jimenez, R. Leal, and M. D. Appleman. 1996. Comparative in vitro activity of trovafloxacin (TV) with ten other agents against 275 strains of aerobic and anaerobic organisms isolated from patients with intraabdominal infection, abstr. E80, p. 95. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. 1a. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of CP-99,219, a new fluoroquinolone against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
3. Girard, A. E., D. Girard, T. D. Gootz, J. A. Faiella, and C. R. Cimochowski. 1995. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens. Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob. Agents Chemother. 39:2210-2216.
4. Goldstein, E. J. C., and D. M. Citron. 1992. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990. and WIN 57273 against anaerobic bacteria. Antimicrob. Agents Chemother. 36:1158-1162.
5. Gooding, B. B., and R. N. Jones. 1993. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob. Agents Chemother. 37:349-353. (Erratum, 38:909).
6. Marshall, S. A., and R. N. Jones. 1993. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone. Antimicrob. Agents Chemother. 37:2747-2753.
7. Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.). 1995. Manual of clinical microbiology, 6th ed. ASM Press, Washington, D.C.
8. National Committee for Clinical Laboratory Standards. 1993. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 3rd ed. Approved standard M11-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
9. National Committee for Clinical Laboratory Standards. 1994. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. M7-T2. National Committee for Clinical Laboratory Standards. Vil-lanova, Pa.
10. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, piperacillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. 38:2471-2476.
11. Summanen, P. E., E. J. Baron, D. M. Citron, C. A. Strong, H. M. Wexler, and S. M. Finegold. 1993. Wadsworth anaerobic bacteriology manual, 5th ed. Star Publishing Co., Belmont, Calif.
12. Wexler, H. M., E. Molitoris, D. Molitoris, and S. M. Finegold. 1996. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob. Agents Chemother. 40:2232-2235.